By Dennis Thompson HealthDay ReporterWEDNESDAY, Jan. 7, 2026 (HealthDay News) — Ozempic and Wegovy might help people avoid colon cancer as well as promote weight loss or control diabetes, a new study says.

Novo Nordisk’s new Wegovy pill hit the market this week. The Danish drug maker, best known for GLP-1 injections like Ozempic and Wegovy, is now the first company to manufacture and receive FDA approval for an oral GLP-1 pill for weight management.

A recent study revealed that GLP-1 drugs, Ozempic and Wegovy, primarily used for diabetes and weight loss, may assist in minimizing the risk of colon cancer.According to the research which is set to be presented at the American Society of

Weight loss and diabetes drugs such as Ozempic and Wegovy may help reduce colon cancer risk, a new study presented at the American Society of Clinical Oncology found. Researchers reported a 36% lower risk among people using GLP-1 drugs compared to aspirin,

When used with the appropriate medical guidance, GLP-1 medications like Ozempic, Wegovy and Mounjaro can be an effective route to sustainable weight loss. One such route is, of course, through the NHS,

Ozempic and Wegovy – two brand-name semaglutide drugs prescribed for diabetes and weight loss – will lose market exclusivity in Canada in January. That means generic pharmaceutical companies can launch versions of semaglutide, which could lead to prices falling by 65 per cent.

TORONTO — Novo Nordisk Canada is considering competing with generic versions of its brand-name Ozempic and Wegovy drugs by introducing renamed, lower-priced copies of the medications. Health Canada approved the company’s submissions for Plosbrio and Poviztra on Dec. 22.

The lowest doses of the daily pill will cost $149 a month for people paying out of pocket, offering a cheaper alternative to injectable weight loss drugs.

The impact of popular U. S. weight-loss drugs like Ozempic and Wegovy (GLP-1 receptor agonists), upon their initial introduction to Americans, is showing many effects beyond just improving personal health.

Danish pharmaceutical giant Novo Nordisk has officially launched its once-daily Wegovy weight-loss pill in the United States, intensifying competition in the rapidly growing obesity drug market. The oral medication,